Leishmaniasis is endemic in the south of France, where autochthonous disease is caused by *Leishmania infantum*, and affects both humans and dogs. The prevalence of canine leishmaniasis is between 3 and 66% depending on the region and the methods used. Human leishmaniases are also imported into France, mainly from French Guiana and North Africa. The surveillance of autochthonous and imported human leishmaniases is based on passive notification to the National Reference Centre for Leishmaniases (NRCL) created in 1998. Between 1999 and 2012, 317 autochthonous and 1,154 imported cases were notified to the NRCL. The average number of autochthonous cases notified per year was 22.6, mainly cases of visceral leishmaniasis (84.5%). All cases were infected in the south of France. Leishmaniasis incidence is 0.22 per 100,000 inhabitants in the endemic area. Imported cases were more frequent (annual mean of 82.4 cases) and consisted predominantly in cutaneous leishmaniasis (CL) cases (91%), essentially *L. major* CL imported from Maghreb and Sub-Saharan Africa, and *L. guyanensis* CL from French Guiana. This national notification system allowed a better understanding of the incidence and distribution of the disease; it is also useful to assess the temporal-spatial evolution of the disease in France, which appears relatively stable.

**Introduction**

In Europe, leishmaniasis is a zoonosis endemic in countries surrounding the Mediterranean Basin. In France, the French Ministry of Health supported the creation of the National Reference Centre for Leishmaniases (NRCL) in 1998 in Montpellier (http://www.parasitologie.univ-montp1.fr/english_vers/en_index.htm), with the aim of better understanding the epidemiological situation of the human disease at the national level. Its true incidence was unknown and the suspected increase of imported cases and of cases in immunocompromised patients needed to be confirmed. In this context, one of the first activities of the NRCL was to set up a system for notifying autochthonous and imported human leishmaniasis cases in France. This retrospective study reports the results of fourteen years of this surveillance.

**Epidemiological situation of leishmaniases in France**

In France, the endemic area of leishmaniases is restricted to the south of the country. Several foci are clearly identified along the Mediterranean coast from the Spanish to the Italian border: the eastern Pyrénées, the Cévennes, the Provence, the Alpes-Maritimes and Corsica. The transmission is generally rural but two large cities, Nice and Marseille, are known to comprise endemic foci within their boundaries [1,2]. Dogs constitute the main reservoir of the pathogen, and *Leishmania infantum* is the species responsible for all autochthonous cases. Human cases due to this species are reported every year. However, symptomatic visceral leishmaniasis (VL) human cases represent only ‘the tip of the iceberg’ [3]. Indeed, individuals living in endemic areas of *L. infantum* are frequently exposed to biting by the sandfly vector. Epidemiological studies conducted worldwide in endemic areas of *L. infantum* and using leishmanin skin test, serology, blood cultivation or polymerase chain reaction (PCR), strongly suggest that the frequency of asymptomatic carriers is high [reviewed in 3].

Before 1999, there was no established notification of human leishmaniasis cases to the French health system. It was therefore difficult to have a precise picture of the incidence and prevalence of leishmaniases in France. Yet, the mean annual incidence of autochthonous VL in France was estimated for the years from 1989 to 1995 at around 1.3, 0.66 and 0.22 cases per...
The phlebotomine sandfly vector
In France, the disease is spread by sandflies of the genus *Phlebotomus*, specifically *P. perniciosus* and *P. ariasi*, which have a seasonal activity, generally from May/June to September/October [7,8]. In southern France, *P. perniciosus* represents the most common vector species; it is mainly present in rural and peri-urban areas and preferentially at altitudes less than 600 m above sea level. *P. ariasi*, in contrast, is found preferentially in rural areas at altitudes between 200 and 1,400 m above sea level; it represents the main vector in the Cévennes and Pyrénées-Orientales foci [9, reviewed in 10].

The canine reservoir
Canine leishmaniasis, affecting essentially the domestic dog (Canis familiaris), is endemic in the regions confined by a triangle of which the apex corresponds to the departments (French administrative territorial divisions) of Ardèche and Drôme and the base to the Mediterranean coast. Two national surveys, performed in 1987 and 2004 and exclusively based on reports from veterinary clinics [11,12], led to the creation of a map displaying the endemic geographical areas and the changing profile of the disease, by comparing maps over an interval of almost 20 years. The information was completed by a retrospective database search and mapping about canine leishmaniasis covering the period 1965 to 2007 [13]. The results show that the disease is still prevalent in southern France, including Ardèche, and that new endemic areas emerge, contiguous to pre-existing endemic foci. Overall, 25 of 95 departments are affected; but for several of them, very low numbers of cases were reported [13,14], questioning the endemic nature of the disease in these areas and reducing the main endemic region to the 12 departments closest to the Mediterranean Sea. The seroprevalence in dogs in the latter ranges from 8.1 to 28% [11, reviewed in 1].

In the Cévennes focus, a study conducted in 1997, showed that among 253 domestic dogs tested serologically, 29.6% were positive and 70% of them presented clinical signs of leishmaniasis [6]. However, in the same survey, using an ultrasensitive PCR assay, the overall prevalence of parasite carriage was found at 80%; and at least 65% of asymptomatic dogs were found harbouring circulating parasites in their blood [6]. Thus, asymptomatic dogs can act as a reservoir of the parasite and seem to allow the transmission and spread of leishmaniasis [reviewed in 15-17]. Another study modelling previous surveys of canine leishmaniasis estimated the prevalence between 5.4 and 20.3% [18].

Human cases
It is not easy to get an accurate picture of the disease progression in humans in southern France during the twentieth century [1]. According to literature data, at least 200 cases of leishmaniasis were recorded between 1918 and 1975, and a further 22 cases from 1975 to 1984 and 65 cases from 1985 to 1992 [unpublished data, 1, 4, 19]. To our knowledge, a single attempt was made in the past to prospectively record all national cases of VL during two years (1986-87) [20]: a total of 89 patients were recorded, of which 70 acquired the disease in France.

The objectives of the present study are to update these data and to report the results obtained by the NRCL in the surveillance of the human disease in France between 1999 and 2012.

Methods
All leishmaniasis cases notified in France between 1999 and 2012 were analysed according to the place of infection, clinical presentation of the disease, age and risk factors for immunosuppression. For reasons of data completeness, only the period from 2007 to 2012 was analysed for risk factors.

French Guiana (a French overseas territory located in South America) is an endemic area for leishmaniasis [21-23]. Although the Parasitology-Mycology Department of the University Hospital of Cayenne is associated with the NRCL, the focus of the analyses presented here is Europe, and thus cases diagnosed in French Guiana are not included in this study. However, cases imported from French Guiana and diagnosed in France are included.

Cases confirmed by at least one specific biological test could be notified to the CNRL. Data were obtained via the standard reporting form created in 1998 at the NRCL. This form is available online (http://www.parasitologie.univ-montp1.fr/doc/Declaration_pub_2011.pdf) and can be sent back after anonymisation of the data, by mail or email but it cannot be filled online. The notification is not compulsory. It is made on a voluntary basis and relies mainly on care facilities supporting patients. The following characteristics are specified on the form: age (children defined as <16 years old), sex, risk factors with particular reference to immunosuppressive conditions such as organ or bone marrow transplantation, human immunodeficiency virus (HIV) infection, immunosuppressive therapy, leukaemia, solid organ cancer, clinical features (for VL: pancytopenia, splenomegaly, hepatomegaly, fever, weight loss; for CL or MCL: number of lesions, localisation, type of lesions such as ulceration, nodule) duration of symptoms, the presumed place of infection and laboratory tests performed for diagnosis.

Results
During a period of 14 years between 1999 and 2012, the NRCL received notifications of 317 and 1,142
autochthonous and imported cases of leishmaniasis, respectively, as well as 12 (visceral) cases of undetermined origin (Figure 1). More than 70 health centres notified cases: they were mostly university hospital centres but also general hospital centres, the health services of the French army, and occasionally private medical clinics or even a few practitioners.

**Autochthonous human leishmaniasis cases**

Of the 317 cases of autochthonous leishmaniasis 268 (84.5%) were VL cases, 39 (12.3%) cutaneous leishmaniasis (CL) and 10 (3.1%) mucocutaneous leishmaniasis (MCL) cases.

The ratio of men to women was 1.8 and the disease affected mostly adults (222 cases; 70%); among those, 50 were over 60 years old; 73 patients (23%) were less than five years old; the mean age of the patients was 35.5 years and the median 39 years (range 1 to 89 years).

Figure 2 shows the number of autochthonous annual cases from 1999 to 2012 according to the clinical presentation. For the whole metropolitan France, the average number of notified cases per year was 22.6 (ranging from 14 in 2010 to 35 in 2001). Infection occurred in the south of France in all cases. The mean annual incidence of leishmaniasis that may be inferred from these data is 0.21 per 100,000 inhabitants for the endemic area and 0.26 for the eight most affected departments (Figure 3); it varies from 0.64 (Alpes Maritimes) to 0.01 (Aude) per 100,000 inhabitants.

**Visceral leishmaniasis cases**

VL was the predominant clinical presentation (268/317; 84.5%), with a mean of 19.1 (ranging from 5 to 31) cases per year, and a peak at 32 VL cases in 2001. The two
departments with the highest number of notified VL cases are the Alpes-Maritimes (97 cases) and Bouches-du-Rhône (46 cases) (Figure 3).

An analysis of our data over the period 2007 to 2012 shows that VL cases occurred in 62% (90/145) in men and more frequently (46.9%; 68/145) in the age group 20 to 60 years; 19.3% (28/145) of the cases were observed in people over 60 years (Figure 4).

Cutaneous leishmaniasis and mucocutaneous leishmaniasis cases
Since 1999, only 39 cases of CL and 10 of MCL have been reported. Autochthonous CL, with a mean of 2.8 cases (ranging from 0 to 8) per year. With respect to MCL, only 10 cases have been reported, including three from Eastern Pyrénées. MCL was essentially a primary condition of mucosae, with neither visceral, nor purely cutaneous involvement.

Imported leishmaniasis cases
Between 1999 and 2012, 1,154 imported cases were reported to the NRCL, a mean of 82.4 cases (range 37 to 148) annually. Only 98 of these were VL cases, resulting in an annual mean of seven cases. CL cases represented 91% (1,051/1,154) of the total: 41.9% (440/1,051) of these were from Africa, originating from North Africa in 30.9% (325/1,051) of cases and in sub-Saharan Africa in 11% (115/1,051). Imported CL cases acquired in French Guiana represented 41.7% (438/1,051) of the notified cases (only 44 cases, 4.2% of them having been infected in the rest of Latin America). These three geographical areas correspond to the main migratory movements to metropolitan France.

Molecular strain typing from the Old World cases for the years 2009 to 2011, identified a large majority (141 cases; 88%) of *L. major*, followed by *L. tropica* (18 cases; 11%); for the New World cases, *L. guyanensis* was largely predominant (170 cases; 85%), followed by *L. braziliensis* (27 cases; 13%). It is of note that imported cases from French Guiana reported to the NRCL are not necessarily representative of the epidemiological situation of this region.

Autochthonous and imported visceral leishmaniasis cases and immunocompromising conditions
Taking into account all VL cases (n=366) reported to the NRCL from 1999 to 2012, 268 autochthonous cases and 98 imported cases, data analysis showed the association of an immunocompromising condition in 44.3% of cases (162/366): 31.4% (115/366) were HIV infected, 9.6% (35/366) had an immunosuppressive treatment and 3.3% (12/366) had received an organ or bone marrow transplant.

Discussion and conclusion
In France, autochthonous leishmaniasis is due to *L. infantum* and is endemic mainly in the Mediterranean region. Canine leishmaniasis remains widespread in these foci and is the subject of studies by the ANSES (National Agency for Health Security of Food and Environment) as well as several national veterinary (Lyon, Maisons-Alfort, Nantes) or medical (Nice, Marseille) faculties, often in collaboration with the NRCL. With respect to human cases, the creation of a notification system at the NRCL in 1999 has allowed a better understanding of the incidence and distribution
of the disease. Although an increase in incidence or an extension of the endemic areas can be anticipated in view of global warming [24,25], it appears that autochthonous cases remain relatively rare (annual mean 22.6) in France with a clear predominance of VL (84.5%).

VL has long been considered a disease of young children. The first case of Mediterranean kala-azar in a child in France was reported in 1918 [26]. A national survey conducted in 1986-87 showed a predominance of the disease in children, which constituted 51% of cases, with equal distribution between both sexes [20]. However, over the last decades, with the emergence of immunosuppression and primarily of HIV / acquired immunodeficiency syndrome (AIDS), the epidemiology of the disease has changed: in particular, the incidence in adults has increased significantly. Indeed, between 1975 and 2004, children accounted for only 30% of the cases [1]. This can be partly correlated with the increasing number of cases of leishmaniasis/HIV co-infection: HIV-positive patients are at high risk, and leishmaniasis is considered an opportunistic disease [27,28]. Between 1996 and 1998, 50% of new VL cases in southwestern Europe (including France) involved HIV-positive patients [27]. The mean age in our adult patients with VL was 36 years [28]. Nevertheless, the occurrence of cases among the elderly was not exceptional, which may be explained by ageing, declining of immune system, association with other pathologies such as tumours, inflammatory diseases, VL can also affect patients with no apparent immunosuppression nor risk factor, irrespective of their age. Overall, the incidence of VL during the study period was relatively stable, but a decrease of the incidence can be noted if compared to the period from 1993 to 1997 [1, 2], this
being most likely linked with the introduction of highly active antiretroviral therapy in AIDS patients.

In contrast to VL, autochthonous cases of CL and MCL are rare in France [29] and appear sporadic. CL is probably underdiagnosed and certainly undernotified, to a great extent because cutaneous lesions due to *L. infantum* are often small, painless and spontaneously self-curing within a few months; hence these benign lesions are essentially seen by general practitioners or dermatologists, which generally do not notify cases. The number of MCL cases notified to the NRCL, however, reflects almost the whole of the total seen in France, as this atypical clinical presentation necessitates the implementation of a specific laboratory diagnosis and initiation of anti-*Leishmania* drug treatment.

Compared to autochthonous cases, the number of imported cases is relatively high with an annual mean of 82.4 cases, mainly consisting in CL cases due to *L. major* and *L. guyanensis*, while for VL cases the annual mean of seven is not far from the nine cases per year reported in 1986-87 [20].

The monitoring by the NRCL is also useful to assess the temporal-spatial evolution of the disease. It is difficult to infer from these data whether the incidence of autochthonous leishmaniasis is declining in France or not: certain data sets suggest a medium-term (over decades) tendency to decline [1,2,20], but our data show that it is currently relatively stable. As to the risk of seeing the emergence of ‘exotic’ or hybrid parasites [30] which would be transmitted locally by permissive phlebotomine vectors, we consider that it is almost null. Indeed, (i) there is no evidence for any permissivity of *P. perniciosus* and *P. ariasi*; (ii) the probability of this occurring in nature appears extremely low, as, on top of permissivity, it requires gathering a number of factors allowing transmission (southern France, summer season, absence of treatment, etc.).

The Working Group for the Notification of Human Leishmanioses in France

(In alphabetical order and in addition to the main authors)

Y Balard (Centre National de Référence des Leishmanioses, Montpellier), P Delaunay (CHU Nice), S Hamane (CHU Saint Louis, Paris), H Yéra (CHU Cochin, Paris), S Houzé (CHU Bichat, Paris), A Izri (CHU Avicenne, Paris), E Lightburne (Services de Santé des Armées Lavéran, Marseille), Charles Mary (CHU La Timone, Marseille), Gloria Morizot (Institut Pasteur, Paris), Tiphaine Merguey (CHU de Rennes), Renaud Piarroux (CHU La Timone, Marseille), Christelle Pomares (CHU Nice), Francine Pratlong (Centre National de Référence des Leishmanioses, Montpellier), Claudine Sarfati (CHU Saint Louis, Paris).

Acknowledgements

We warmly thank all the centers who notified leishmaniasis cases to the NRCL over the whole of this period, and regret not to be able to name all our correspondents individually. We also acknowledge the technical help of Patrick Lami and Loïc Talignani for in vitro cultivation, of Ghislaine Serres for molecular identification of the strains and of Yves Balard for creating the distribution maps.